



○ Innovative Science

○ Breakthrough Therapies

○ Clinical Advances

JS-K and PABA/NO as Antitumor Agents




TEDCO/NIH/NCI Technology Showcase

Larry Keefer, NCI

September 25, 2007




JS-K Slows Multiple Myeloma Xenograft Growth...




Kiziltepe et al., Blood 2007, 110, 709-718.

...and Greatly Prolongs Survival.



Kiziltepe et al., Blood 2007, 110, 709-718.

JS-K Slows Leukemia Xenograft Growth....




Shami et al., Mol Cancer Ther 2003, 2, 409-417.


*....and Induces Major Tumor Necrosis
in Vivo.*



**Control
HL-60**



**JS-K
HL-60**




Shami et al., Mol Cancer Ther 2003, 2, 409-417.

JS-K Is Also Active in Vivo Against:



- **Human prostate cancer xenografts;**
Shami et al., Mol Cancer Ther 2003, 2, 409-417.
- **Orthotopic rat liver cancer.**
Shami et al., J Med Chem 2006, 49, 4356-4366.

*PABA/NO Slows Ovarian Cancer
Xenograft Growth Comparably to Cisplatin*



Findlay et al., *Mol Pharmacol* 2004, 65, 1070-1079.

For further information



- **Tech transfer (CDAs, CRADAs):**
Dr. Nadezda Radoja, radojan@mail.nih.gov, 301-846-5222
- **Licensing:**
Dr. Norbert Pontzer, PontzerN@OD.NIH.GOV, 301-435-5502
- **Biology:**
Dr. Paul Shami, p.shami@m.cc.utah.edu, 801-585-5136
- **Chemistry:**
Dr. Larry Keefer, keefer@ncicrf.gov, 301-846-1467